1
|
Crowell LE, Lu AE, Love KR, Stockdale A, Timmick SM, Wu D, Wang Y(A, Doherty W, Bonnyman A, Vecchiarello N, Goodwine C, Bradbury L, Brady JR, Clark JJ, Colant NA, Cvetkovic A, Dalvie NC, Liu D, Liu Y, Mascarenhas CA, Matthews CB, Mozdzierz NJ, Shah KA, Wu SL, Hancock WS, Braatz RD, Cramer SM, Love JC. On-demand manufacturing of clinical-quality biopharmaceuticals. Nat Biotechnol 2018; 36:nbt.4262. [PMID: 30272677 PMCID: PMC6443493 DOI: 10.1038/nbt.4262] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Accepted: 08/27/2018] [Indexed: 12/18/2022]
Abstract
Conventional manufacturing of protein biopharmaceuticals in centralized, large-scale, single-product facilities is not well-suited to the agile production of drugs for small patient populations or individuals. Previous solutions for small-scale manufacturing are limited in both process reproducibility and product quality, owing to their complicated means of protein expression and purification. We describe an automated, benchtop, multiproduct manufacturing system, called Integrated Scalable Cyto-Technology (InSCyT), for the end-to-end production of hundreds to thousands of doses of clinical-quality protein biologics in about 3 d. Unlike previous systems, InSCyT includes fully integrated modules for sustained production, efficient purification without the use of affinity tags, and formulation to a final dosage form of recombinant biopharmaceuticals. We demonstrate that InSCyT can accelerate process development from sequence to purified drug in 12 weeks. We used integrated design to produce human growth hormone, interferon α-2b and granulocyte colony-stimulating factor with highly similar processes on this system and show that their purity and potency are comparable to those of marketed reference products.
Collapse
Affiliation(s)
- Laura E. Crowell
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - Amos E. Lu
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - Kerry R. Love
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
| | - Alan Stockdale
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
| | - Steven M. Timmick
- Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York,
USA
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York,
USA
- GlaxoSmithKline, King of Prussia, Pennsylvania, USA
| | - Di Wu
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University, Boston,
Massachusetts, USA
| | - Yu (Annie) Wang
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University, Boston,
Massachusetts, USA
| | - William Doherty
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
| | - Alexandra Bonnyman
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
| | - Nicholas Vecchiarello
- Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York,
USA
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York,
USA
| | - Chaz Goodwine
- Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York,
USA
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York,
USA
| | | | - Joseph R. Brady
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - John J. Clark
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Biogen, Cambridge, Massachusetts, USA
| | - Noelle A. Colant
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
- Department of Biochemical Engineering, University College London, London, England
| | - Aleksandar Cvetkovic
- Pall Life Sciences, Westborough, Massachusetts, USA
- Sanofi, Framingham, Massachusetts, USA
| | - Neil C. Dalvie
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - Diana Liu
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
| | - Yanjun Liu
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University, Boston,
Massachusetts, USA
| | - Craig A. Mascarenhas
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - Catherine B. Matthews
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - Nicholas J. Mozdzierz
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - Kartik A. Shah
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
| | | | - William S. Hancock
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University, Boston,
Massachusetts, USA
| | - Richard D. Braatz
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - Steven M. Cramer
- Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York,
USA
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York,
USA
| | - J. Christopher Love
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| |
Collapse
|
2
|
Wang YA, Wu D, Auclair JR, Salisbury JP, Sarin R, Tang Y, Mozdzierz NJ, Shah K, Zhang AF, Wu SL, Agar JN, Love JC, Love KR, Hancock WS. Integrated Bottom-Up and Top-Down Liquid Chromatography-Mass Spectrometry for Characterization of Recombinant Human Growth Hormone Degradation Products. Anal Chem 2017; 89:12771-12777. [PMID: 29096433 DOI: 10.1021/acs.analchem.7b03026] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
With the advent of biosimilars to the U.S. market, it is important to have better analytical tools to ensure product quality from batch to batch. In addition, the recent popularity of using a continuous process for production of biopharmaceuticals, the traditional bottom-up method, alone for product characterization and quality analysis is no longer sufficient. Bottom-up method requires large amounts of material for analysis and is labor-intensive and time-consuming. Additionally, in this analysis, digestion of the protein with enzymes such as trypsin could induce artifacts and modifications which would increase the complexity of the analysis. On the other hand, a top-down method requires a minimum amount of sample and allows for analysis of the intact protein mass and sequence generated from fragmentation within the instrument. However, fragmentation usually occurs at the N-terminal and C-terminal ends of the protein with less internal fragmentation. Herein, we combine the use of the complementary techniques, a top-down and bottom-up method, for the characterization of human growth hormone degradation products. Notably, our approach required small amounts of sample, which is a requirement due to the sample constraints of small scale manufacturing. Using this approach, we were able to characterize various protein variants, including post-translational modifications such as oxidation and deamidation, residual leader sequence, and proteolytic cleavage. Thus, we were able to highlight the complementarity of top-down and bottom-up approaches, which achieved the characterization of a wide range of product variants in samples of human growth hormone secreted from Pichia pastoris.
Collapse
Affiliation(s)
- Yu Annie Wang
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University , 360 Huntington Avenue, Boston, Massachusetts 02115, United States
| | - Di Wu
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University , 360 Huntington Avenue, Boston, Massachusetts 02115, United States
| | - Jared R Auclair
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University , 360 Huntington Avenue, Boston, Massachusetts 02115, United States
| | - Joseph P Salisbury
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University , 360 Huntington Avenue, Boston, Massachusetts 02115, United States
| | - Richa Sarin
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University , 360 Huntington Avenue, Boston, Massachusetts 02115, United States
| | - Yang Tang
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University , 360 Huntington Avenue, Boston, Massachusetts 02115, United States
| | - Nicholas J Mozdzierz
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology , 500 Main Street, Cambridge, Massachusetts 02142, United States
| | - Kartik Shah
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology , 500 Main Street, Cambridge, Massachusetts 02142, United States
| | - Anna Fan Zhang
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University , 360 Huntington Avenue, Boston, Massachusetts 02115, United States
| | - Shiaw-Lin Wu
- BioAnalytix Inc. , 790 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Jeffery N Agar
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University , 360 Huntington Avenue, Boston, Massachusetts 02115, United States
| | - J Christopher Love
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology , 500 Main Street, Cambridge, Massachusetts 02142, United States
| | - Kerry R Love
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology , 500 Main Street, Cambridge, Massachusetts 02142, United States
| | - William S Hancock
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University , 360 Huntington Avenue, Boston, Massachusetts 02115, United States
| |
Collapse
|
3
|
Sockolosky JT, Szoka FC. Periplasmic production via the pET expression system of soluble, bioactive human growth hormone. Protein Expr Purif 2013; 87:129-35. [PMID: 23168094 PMCID: PMC3537859 DOI: 10.1016/j.pep.2012.11.002] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2012] [Revised: 11/07/2012] [Accepted: 11/08/2012] [Indexed: 10/27/2022]
Abstract
A pET based expression system for the production of recombinant human growth hormone (hGH) directed to the Escherichia coli periplasmic space was developed. The pET22b plasmid was used as a template for creating vectors that encode hGH fused to either a pelB or ompA secretion signal under control of the strong bacteriophage T7 promoter. The pelB- and ompA-hGH constructs expressed in BL21 (λDE3)-RIPL E. coli are secreted into the periplasm which facilitates isolation of soluble hGH by selective disruption of the outer membrane. A carboxy-terminal poly-histidine tag enabled purification by Ni(2+) affinity chromatography with an average yield of 1.4 mg/L culture of purified hGH, independent of secretion signal. Purified pelB- and ompA-hGH are monomeric based on size exclusion chromatography with an intact mass corresponding to mature hGH indicating proper cleavage of the signal peptide and folding in the periplasm. Both pelB- and ompA-hGH bind the hGH receptor with high affinity and potently stimulate Nb2 cell growth. These results demonstrate that the pET expression system is suitable for the rapid and simple isolation of bioactive, soluble hGH from E. coli.
Collapse
Affiliation(s)
- Jonathan T. Sockolosky
- Pharmaceutical Sciences and Pharmacogenomics Graduate Program, Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, 513 Parnassus Ave., Box 0912, San Francisco, California, 94143, USA
| | - Francis C. Szoka
- Pharmaceutical Sciences and Pharmacogenomics Graduate Program, Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, 513 Parnassus Ave., Box 0912, San Francisco, California, 94143, USA
| |
Collapse
|
4
|
Lispi M, Datola A, Bierau H, Ceccarelli D, Crisci C, Minari K, Mendola D, Regine A, Ciampolillo C, Rossi M, Giartosio CE, Pezzotti AR, Musto R, Jone C, Chiarelli F. Heterogeneity of commercial recombinant human growth hormone (r-hGH) preparations containing a thioether variant. J Pharm Sci 2010; 98:4511-24. [PMID: 19408342 DOI: 10.1002/jps.21774] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The objective of the present study was to assess (I) the potential presence of a recently discovered thioether variant in commercially available recombinant human growth hormone (r-hGH) preparations, and (II) the impact of the thioether modification on the in-vivo bioactivity and the receptor binding kinetics. Samples were tested employing European (EP) and US Pharmacopeia (USP) Somatropin monograph and mass spectrometry methods. None of the international standards contained this variant. All products conformed to EP specifications but six out of eight lots contained the variant. An artificially enriched thioether sample exhibited a significantly reduced in vivo biopotency and altered receptor-binding properties compared with a control. The absence of the variant in the pituitary hGH standard, and the possibility to generate it artificially suggests that it is not naturally occurring and that it may arise from an uncontrolled manufacturing process. Controlled studies may be required to assess its clinical efficacy and safety. EP and USP methods may need to be adapted to reliably detect the presence of the variant.
Collapse
Affiliation(s)
- Monica Lispi
- Medical Liaison Office, Merck Serono S.p.A., Roma, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Abstract
Human growth hormone (GH) is a heterogeneous protein hormone consisting of several isoforms. The sources of this heterogeneity reside at the level of the genome, mRNA splicing, post-translational modification and metabolism. The GH gene cluster on chromosome 17q contains 2 GH genes (GH1 or GH-N and GH2 or GH-V) in addition to 2(-3) genes encoding the related chorionic somatomammotropin. Alternative mRNA splicing of the GH1 transcript yields two products: 22K-GH (the principal pituitary GH form) and 20K-GH. Post-translationally modified GH forms include N(alpha)-acylated, deamidated and glycosylated monomeric GH forms, as well as both non-covalent and disulfide-linked oligomers up to at least pentameric GH. GH fragments generated in the course of peripheral metabolism may be measured in immunoassays for GH. The GH-N gene is expressed in the pituitary, the GH-V gene in the placenta. Secretion of pituitary GH forms is pulsatile under control from the hypothalamus, whereas secretion of placental GH-V is tonic and rises progressively in maternal blood during the 2nd and 3rd trimester. Pituitary GH forms are co-secreted during a secretory pulse; no isoform-specific stimuli have been identified. There are minor differences in somatogenic and metabolic bioactivity among the GH isoforms, depending on species and assay system used. Both 20K-GH and GH-V have poor lactogenic activity. Oligomeric GH forms have variably diminished bioactivity compared to monomeric forms. GH isoforms cross-react in most immunoassays, but assays specific for 22K-GH, 20K-GH and GH-V have been developed. The metabolic clearance of 20K-GH and GH oligomers is delayed compared to that of 22K-GH. The heterogeneous mixture of GH isoforms in blood is further complicated by the presence of two GH-binding proteins, which form complexes with GH; isoform proportions also vary depending on the lag time from a secretory pulse because of different half-lives. GH forms excreted in the urine reflect monomeric GH isoforms in blood, but constitute only a minute fraction of the GH production rate. The heterogeneity of GH is one important reason for the notorious disparity among assay results. It also presents an opportunity for distinguishing endogenous from exogenous GH.
Collapse
Affiliation(s)
- Gerhard P Baumann
- Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 303 E. Chicago Avenue, Chicago, Illinois 60611, USA.
| |
Collapse
|
6
|
Jiang H, Wu SL, Karger BL, Hancock WS. Mass spectrometric analysis of innovator, counterfeit, and follow-on recombinant human growth hormone. Biotechnol Prog 2009; 25:207-18. [DOI: 10.1002/btpr.72] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
7
|
Kim TG, Baek MY, Lee EK, Kwon TH, Yang MS. Expression of human growth hormone in transgenic rice cell suspension culture. PLANT CELL REPORTS 2008; 27:885-91. [PMID: 18264710 DOI: 10.1007/s00299-008-0514-0] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/22/2007] [Revised: 01/07/2008] [Accepted: 01/27/2008] [Indexed: 05/22/2023]
Abstract
Human growth hormone (hGH), a pituitary-derived polypeptide, evidences a wide range of biological functions, including protein synthesis, cell proliferation, and metabolism. A synthetic hGH gene (shGH) has been synthesized on the basis of plant-optimized codon usage via an overlap PCR strategy and located in a plant expression vector under the control of the rice amylase 3D (Ramy3D) promoter, which is induced by sugar starvation. The plant expression vector was introduced into rice calli (Oryza sativa L. cv. Donjin) via particle bombardment transformation methods. The integration of the shGH gene into the chromosome of the transgenic rice callus was verified via genomic DNA PCR amplification and shGH expression in transgenic rice suspension cells was confirmed via Northern blot analysis. The shGH protein was detected in the transgenic rice cell suspension culture medium following induction with sugar starvation, using Western blot analysis. The quantity of shGH that accumulated in the transgenic rice cell suspension medium was 57 mg/l. The shGH accumulated in the transgenic rice cell suspension culture medium evidenced a biological activity similar to that of Escherichia coli-derived recombinant hGH. These results indicate that the shGH was generated and accumulated in the transgenic rice cell suspension culture medium, and manifested biological activity.
Collapse
Affiliation(s)
- Tae-Geum Kim
- Division of Biological Sciences and the Research Center for Bioactive Materials, Chonbuk National University, Jeonju 561-756, South Korea
| | | | | | | | | |
Collapse
|
8
|
Russell DA, Spatola LA, Dian T, Paradkar VM, Dufield DR, Carroll JA, Schlittler MR. Host limits to accurate human growth hormone production in multiple plant systems. Biotechnol Bioeng 2005; 89:775-82. [PMID: 15696512 DOI: 10.1002/bit.20366] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Human growth hormone (hGH) is not only a valuable recombinant therapeutic protein for hormone deficiency indications, but is also an extensively characterized molecule both from recombinant bacterial systems and as circulating in humans. We describe the characterization of hGH produced in three different plant systems: tobacco cell culture, soy seed, and maize seed. The data indicate highest production in the maize seed system, with continued productivity over multiple generations, and when bred to a new host genotype for improved productivity. Purification indicated significant material of the correct structure from both plant cell culture and maize seed, with maize seed also showing correct activity relative to that produced by Escherichia coli. However, all systems showed some proteolyzed hGH, with data from gel electrophoresis, mass spectrometry, and peptide mapping localizing to a region of the protein also prone to cleavage in some other systems. Together, the data indicate the dependence of recombinant protein accumulation on posttranslational processes in different host systems.
Collapse
Affiliation(s)
- Douglas A Russell
- Agracetus Campus-Monsanto, P.O. Box 620999, Middleton, Wisconsin 53562, USA.
| | | | | | | | | | | | | |
Collapse
|
9
|
Jung C, Lee YP, Jeong YR, Kim JY, Kim YH, Kim HS. Characterization of Nα-acetyl methionyl human growth hormone formed during expression in Saccharomyces cerevisiae with liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 814:53-9. [PMID: 15607707 DOI: 10.1016/j.jchromb.2004.09.060] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2004] [Accepted: 09/30/2004] [Indexed: 10/26/2022]
Abstract
We found a new variant of human growth hormone (hGH) from the recombinant hGH expression process in Saccharomyces cerevisiae. The variant was identified as N(alpha)-acetyl methionyl hGH which may be formed by N(alpha)-acetylation of met-hGH during the intracellular expression of hGH in S. cerevisiae. The variant was isolated from manufacturing process of LG Life Sciences' hGH product. The variant was subjected to trypsin digestion and RP-HPLC analysis, resulting in a delayed retention time and an increased mass (173 Da) of T1 tryptic peptide. The amino acid composition and amino acid sequence of the peptide showed the same result with T1 peptide of met-hGH except the N-terminal modification on methionine in the variant peptide. With collision induced dissociation (CID) experiments of the variant T1 tryptic peptide, we found the sequence and the a(1) fragment of N-terminal residue matched with those of acetyl-methionyl hGH. Within our production process, we produce the methionyl hGH first and then use the aminopeptidase to cut the N-terminal methionine. So the acetylation may inhibit the aminopeptidase to remove methionine and produces N(alpha)-acetyl methionyl hGH. And the biological activity of the variant was comparable to one of the unmodified hGH when tested by rat weight gain bioassay.
Collapse
Affiliation(s)
- Chulho Jung
- LG Life Sciences Ltd/R&D Park, 104-1 Munji-dong, Yuseong-gu, Daejeon 305-380, South Korea
| | | | | | | | | | | |
Collapse
|
10
|
Arámburo C, Carranza M, Reyes M, Luna M, Martinez-Coria H, Berúmen L, Scanes CG. Characterization of a bioactive 15 kDa fragment produced by proteolytic cleavage of chicken growth hormone. Endocrine 2001; 15:231-40. [PMID: 11720252 DOI: 10.1385/endo:15:2:231] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
There is evidence for a cleaved form of GH in the chicken pituitary gland. A 25 kDa band of immunoreactive-(ir-)GH, as well as the 22 kDa monomeric form and some oligomeric forms were observed when purified GH or fresh pituitary extract were subjected to SDS-PAGE under nonreducing conditions. Under reducing conditions, the 25 kDa ir-GH was no longer observed, being replaced by a 15 kDa band, consistent with reduction of the disulfide bridges of the cleaved form. The type of protease involved was investigated using exogenous proteases and monomeric cGH. Cleaved forms of chicken GH were generated by thrombin or collagenase. The site of cleavage was found in position Arg133-Gly134 as revealed by sequencing the fragments produced. The NH2-terminal sequence of 40 amino acid residues in the 15 kDa form was identical to that of the rcGH and analysis of the remaining 7 kDa fragment showed an exact identity with positions 134-140 of cGH structure. The thrombin cleaved GH and the 15 kDa form showed reduced activity (0.8% and 0.5% of GH, respectively) in a radioreceptor assay employing a chicken liver membrane preparation. However, this fragment had a clear bioactivity in an angiogenic bioassay and was capable to inhibit the activity of deiodinase type III in the chicken liver.
Collapse
Affiliation(s)
- C Arámburo
- Centro de Neurobiologia, Universidad Nacional Autónoma de México, Querétaro.
| | | | | | | | | | | | | |
Collapse
|
11
|
Hui JO, Chow DT, Markell D, Robinson JH, Katta V, Nixon L, Chang BS, Rohde MF, Haniu M. Identification of Asp95 as the site of succinimide formation in recombinant human glial cell line-derived neurotrophic factor. Arch Biochem Biophys 1998; 358:377-84. [PMID: 9784253 DOI: 10.1006/abbi.1998.0884] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Human glial cell line-derived neurotrophic factor is a single polypeptide of 134 amino acids and functions as a disulfide-linked dimer. Incubation of the protein in pH 5.0 and at 37 degreesC for 1 week showed that 5% of the material was converted to a form that eluted after the major protein peak on a cation-exchange column. The modified component gave an average molecular mass of 30367.0 u (theoretical = 30384.8 u). Within measurement error, this 17.8-u decrease in mass indicated the loss of a water molecule. This observation, together with the protein's behavior on cation-exchange chromatography and the mode of incubation used to generate the modification, was consistent with cyclic imide (succinimide) formation at an aspartyl residue. Hence, only a monomer of the dimeric protein was modified. The modified monomer was purified and subjected to peptic degradation. By a combination of N-terminal analysis and mass spectrometry, the region containing Asp95-Lys96 was identified to be modified. This was further confirmed by carboxypeptidase Y digestion of the modified peptide where the modified region was found to be resistant to further enzymatic degradation. Furthermore, incubation of the modified monomer in pH 8. 5 for 2 h yielded two peaks, in agreement with the succinimide model where the cyclic imide was hydrolyzed into a mixture of isoaspartate and aspartate. Tryptic mapping of the isoaspartyl-containing protein showed that Asp95 was refractory to Edman degradation, confirming it was in the isoaspartate form. Hence, the modification observed was due to succinimide formation at Asp95. This is the first report of succinimide formation at an Asp-Lys linkage.
Collapse
Affiliation(s)
- J O Hui
- Department of Protein Structure, Amgen Inc., Thousand Oaks, California, 91320, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Johnson OL, Jaworowicz W, Cleland JL, Bailey L, Charnis M, Duenas E, Wu C, Shepard D, Magil S, Last T, Jones AJ, Putney SD. The stabilization and encapsulation of human growth hormone into biodegradable microspheres. Pharm Res 1997; 14:730-5. [PMID: 9210189 DOI: 10.1023/a:1012142204132] [Citation(s) in RCA: 147] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
PURPOSE To produce and evaluate sustained-acting formulations of recombinant human growth hormone (rhGH) made by a novel microencapsulation process. METHODS The protein was stabilized by forming an insoluble complex with zinc and encapsulated into microspheres of poly (D,L-lactide co-glycolide) (PLGA) which differed in polymer molecular weight (8-31 kD), polymer end group, and zinc content. The encapsulation procedure was cryogenic, non-aqueous, and did not utilize surfactants or emulsification. The rhGH extracted from each of these microsphere formulations was analyzed by size-exclusion, ion-exchange and reversed-phase chromatography, SDS-polyacrylamide gel electrophoresis, peptide mapping, and cell proliferation of a cell line expressing the hGH receptor. In addition, the in vivo release profile was determined after subcutaneous administration of the microspheres to rats and juvenile rhesus monkeys. RESULTS Protein and bioactivity analyses of the rhGH extracted from three different microsphere formulations showed that the encapsulated protein was unaltered relative to the protein before encapsulation. In vivo, microsphere administration to rats or monkeys induced elevated levels of serum rhGH for up to one month, more than 20-fold longer than was induced by the same amount of protein injected subcutaneously as a solution. The rate of protein release differed between the three microsphere formulations and was determined by the molecular weight and hydrophobicity of the PLGA. The serum rhGH profile, after three sequential monthly doses of the one formulation examined, was reproducible and showed no dose accumulation. CONCLUSIONS Using a novel process, rhGH can be stabilized and encapsulated in a solid state into PLGA microspheres and released with unaltered properties at different rates.
Collapse
Affiliation(s)
- O L Johnson
- Alkermes, Inc., Cambridge, Massachusetts 02139, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Jacobson FS, Hanson JT, Wong PY, Mulkerrin M, Deveney J, Reilly D, Wong SC. Role of high-performance liquid chromatographic protein analysis in developing fermentation processes for recombinant human growth hormone, relaxin, antibody fragments and lymphotoxin. J Chromatogr A 1997; 763:31-48. [PMID: 9129313 DOI: 10.1016/s0021-9673(96)01010-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Development of efficient and reliable fermentation processes for protein pharmaceuticals is aided by the availability of accurate quantitative and qualitative product analyses. We have developed a variety of single and dual column chromatographic separations that meet the needs of process development and examples will be provided of how the resulting data has been used to optimize the culture process. For single column methods, reversed-phase chromatography has been the most versatile, permitting the reliable quantitation of many yeast, Chinese hamster ovary (CHO) cell and Escherichia coli-expressed products in the matrix of culture broth or cell extract. Analysis of secreted human growth hormone synthesized in E. coli, along with clipped and unprocessed forms, will be discussed. Another reversed-phase assay for direct analysis of a peptide product (B-chain relaxin) and its degradation products secreted into E. coli fermentation medium has allowed the purification of the responsible protease. Cation-exchange has proven extremely useful for the direct analysis of antibody fragment synthesized in E. coli, allowing the separation and quantitation of the desired Fab' and Fab'2, as well as the unwanted products of glutathione addition and translational read-through. Assay development is often complicated by the presence of host proteins with chromatographic behavior that is similar to that of the product. Commercial instrumentation now permits the facile development of multidimensional chromatographic assays. We show examples of coupled receptor affinity-reversed-phase assays for a mistranslation product and for covalent multimers of E. coli-synthesized lymphotoxin.
Collapse
Affiliation(s)
- F S Jacobson
- Department of Fermentation and Cell Culture Process Development, Genentech, Inc., South San Francisco, CA 94080, USA
| | | | | | | | | | | | | |
Collapse
|
14
|
McNerney TM, Watson SK, Sim JH, Bridenbaugh RL. Separation of recombinant human growth hormone from Escherichia coli cell pellet extract by capillary zone electrophoresis. J Chromatogr A 1996; 744:223-9. [PMID: 8843671 DOI: 10.1016/0021-9673(96)00421-9] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Free zone capillary electrophoresis (FZCE) was used to resolve recombinant human growth hormone (rhGH) and its variants from very crude mixtures of Escherichia coli (E. coli) cell paste extract. The methodology employs a phosphate deactivated fused-silica capillary and a 250 mM phosphate (pH 6.8), 1% (v/v) propylene glycol buffer with a high field strength of 600 V/cm. Resolution of rhGH and its variants from very crude mixtures did not change after 80 injections for the PSC capillaries. Bare silica and PVA coated capillaries had a more limited lifetime when injected with the same crude mixtures (10 to 30 injections). This FZC method provides a very powerful tool for assessing rhGH modification during the fermentation and isolation of rhGH that is not possible with other current analytical techniques.
Collapse
Affiliation(s)
- T M McNerney
- Department of Manufacturing Science, Genentech, Inc., South San Francisco, CA 94080, USA
| | | | | | | |
Collapse
|
15
|
Johnson OL, Cleland JL, Lee HJ, Charnis M, Duenas E, Jaworowicz W, Shepard D, Shahzamani A, Jones AJ, Putney SD. A month-long effect from a single injection of microencapsulated human growth hormone. Nat Med 1996; 2:795-9. [PMID: 8673926 DOI: 10.1038/nm0796-795] [Citation(s) in RCA: 204] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
An injectable sustained-release form of human growth hormone (hGH) was developed by stabilizing and encapsulating the protein, without altering its integrity, into biodegradable microspheres using a novel cryogenic process. A single injection of microspheres in monkeys resulted in elevated serum levels of recombinant hGH (rhGH) for more than one month. Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-3, both of which are induced by hGH, were also elevated for four weeks by the rhGH containing microspheres to a level greater than that induced by the same amount of rhGH administered by daily injections. These results show that, by using appropriate methods of stabilization and encapsulation, the advantages of sustained-release formulations previously demonstrated for low-molecular-weight drugs can now be extended to protein therapeutics.
Collapse
Affiliation(s)
- O L Johnson
- Alkermes, Inc., Cambridge, Massachusetts 02139, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Mukhija R, Rupa P, Pillai D, Garg LC. High-level production and one-step purification of biologically active human growth hormone in Escherichia coli. Gene X 1995; 165:303-6. [PMID: 8522194 DOI: 10.1016/0378-1119(95)00525-b] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
A plasmid has been constructed to direct the synthesis of recombinant human growth hormone (re-hGH) in Escherichia coli as a fusion protein containing a His6 tag at the N-terminus under the control of the T5 promoter. The re-hGH was synthesized in large amounts and accumulated in the form of inclusion bodies upon induction with IPTG. Inclusion bodies were solubilized in 6 M guanidine.HCl and the re-hGH was purified by single-step affinity chromatography on Ni(2+)-nitrilotriacetic acid (NTA) agarose. At the shake flask level, the purified re-hGH was obtained with a yield of 30 mg/l of culture. The re-hGH was biologically active in a node rat lymphoma (Nb2) cell bioassay.
Collapse
Affiliation(s)
- R Mukhija
- Gene Regulation Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India
| | | | | | | |
Collapse
|
17
|
Battersby JE, Hancock WS, Canova-Davis E, Oeswein J, O'Connor B. Diketopiperazine formation and N-terminal degradation in recombinant human growth hormone. INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH 1994; 44:215-22. [PMID: 7822097 DOI: 10.1111/j.1399-3011.1994.tb00163.x] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
A new degradation process has been identified that occurs in recombinant DNA-derived human growth hormone. Non-enzymatic cyclization of the first two amino acids from the N-terminus and subsequent cleavage results in the formation of a diketopiperazine and a truncated variant of rhGH. The truncated protein was separated using hydrophobic interaction chromatography and identified as desPhe1Pro2-rhGH using N-terminal sequence analysis, tryptic mapping, and mass spectrometry.
Collapse
|
18
|
Jespersen AM, Christensen T, Klausen NK, Nielsen F, Sørensen HH. Characterisation of a trisulphide derivative of biosynthetic human growth hormone produced in Escherichia coli. EUROPEAN JOURNAL OF BIOCHEMISTRY 1994; 219:365-73. [PMID: 8307002 DOI: 10.1111/j.1432-1033.1994.tb19948.x] [Citation(s) in RCA: 66] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
A novel protein derivative has been found during process development of biosynthetic human growth hormone; it has been characterised as human growth hormone with a Cys182-Cys189 trisulphide bridge. We have not been able to find a previous report in the literature about this kind of derivative. The characterisation was obtained partly on the full-length derivative and partly on a tryptic fragment of the derivative. The full-length derivative was characterised by reduction with 1,4-dithiothreitol followed by electrospray mass spectrometry, treatment with cysteine and measurement of hydrogen sulphide liberation upon cysteine treatment. The tryptic fragment from peptide mapping was characterised by amino acid analysis, amino acid sequencing and mass spectrometry. All data indicated an extra sulphur atom in the Cys182-Cys189 cystine bridge.
Collapse
|
19
|
Ghorpade A, Garg LC. Efficient processing and export of human growth hormone by heat labile enterotoxin chain B signal sequence. FEBS Lett 1993; 330:61-5. [PMID: 8370461 DOI: 10.1016/0014-5793(93)80920-p] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The heat-labile enterotoxin chain B (LTB) signal sequence was used for the processing and export of human growth hormone (hGH). The protein was completely processed and exported across the cell membrane to accumulate in the periplasmic space in Escherichia coli. The human growth hormone cDNA was cloned as a PCR amplified fragment under the control of tac promoter and translationally fused to the LTB signal sequence. The rate of processing of hGH under the control of the LTB signal sequence was equal to or more than the rate of induction of expression, indicating efficient processing. The receptor binding activity of the processed periplasmic protein was established in a radio receptor assay.
Collapse
Affiliation(s)
- A Ghorpade
- Gene Regulation Laboratory, National Institute of Immunology, New Delhi, India
| | | |
Collapse
|
20
|
|
21
|
Pearlman R, Bewley TA. Stability and characterization of human growth hormone. PHARMACEUTICAL BIOTECHNOLOGY 1993; 5:1-58. [PMID: 8019691 DOI: 10.1007/978-1-4899-1236-7_1] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- R Pearlman
- Department of Pharmaceutical Research and Development, Genetech, Inc., South San Francisco, California 94080
| | | |
Collapse
|
22
|
Wroblewski VJ. Mechanism of deiodination of 125I-human growth hormone in vivo. Relevance to the study of protein disposition. Biochem Pharmacol 1991; 42:889-97. [PMID: 1867644 DOI: 10.1016/0006-2952(91)90050-f] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Examination of the disposition of proteins employing 125I-labeled tracers can be complicated by the in vivo deiodination of the tracer. The purpose of this study was to characterize the mechanism by which 125I-labeled proteins are deiodinated in vivo using 125I-human growth hormone (hGH) as a model compound. Intravenous (i.v.) administration of 125I-hGH resulted in a biphasic plasma kinetic pattern, with the majority of radioactivity removed from the plasma during the first 15 min. The level of circulating radioactivity at 2 hr was similar to that 15 min after administration. Radioactivity was eliminated from the animals almost exclusively in the urine. The chemical form of radioactivity in the plasma and urine was analyzed by HPLC, and precipitation of radioactivity with silver nitrate or trichloroacetic acid. Fifteen minutes after administration of 125I-hGH, 30% of the circulating radioactivity was present in the form of iodide (125I-). By 2 hr, the majority of radioactivity in the plasma was in the form of 125I-. The radioactivity in the urine was present exclusively in the form of 125I-. In vivo deiodination of 125I-hGH was reflected by the accumulation of radioactivity in the thyroid glands. There was no evidence for the presence of 125I-peptide intermediates in the plasma or urine of treated animals. In vitro, 125I-hGH was degraded to 125I-peptide intermediates by thyroid gland but not liver or kidney homogenates. In the absence of cofactors, 125I- was not observed as an in vitro metabolic product. However, in the presence of dithiothreitol and NADPH as cofactors, the predominant metabolic product formed by thyroid gland homogenates was 125I-. The deiodination of 125I-hGH by thyroid gland homogenates was inhibited by the serine protease inhibitor phenylmethylsulfonyl fluoride (PMSF), indicating that proteolysis of 125I-hGH was required for deiodination to occur. This was supported by the observation that 125I-labeled proteolytic fragments of 125I-hGH, but not 125I-hGH, were deiodinated by liver or kidney homogenates in the presence of these cofactors. Deiodination by thyroid gland homogenates was inhibited by the sulfhydryl-group blocking reagent, iodoacetate, in a concentration-dependent manner. The characteristics of the in vitro deiodination reaction suggest that a form of thyronine 5'-monodeiodinase may be involved in the in vivo deiodination of 125I-hGH and possibly other 125I-proteins. These data suggest that the disposition of proteins may be determined more accurately with 3H-, 14C- or 35S-labeled molecules which better represent the characteristics of the native protein.
Collapse
Affiliation(s)
- V J Wroblewski
- Department of Drug Metabolism and Disposition, Eli Lilly & Company, Indianapolis, IN 46285
| |
Collapse
|